Nangibotide
Also known as: LR12, Motrem
Nangibotide is an investigational TREM-1 inhibitor studied by IV infusion in septic shock. ASTONISH did not meet its primary organ-failure endpoint; later-cutoff biomarker signals remain unconfirmed subgroup findings.
Quick Facts
Identity and clinical development
Nangibotide, also called LR12 or Motrem, is a twelve-amino-acid peptide developed by Inotrem. It is studied in septic shock, where infection causes dangerous hypotension and organ dysfunction. Administration is by IV infusion, and the medicine remains investigational.
TREM-1 amplification and biomarker strategy
The peptide acts as a decoy interfering with triggering receptor expressed on myeloid cells-1, or TREM-1. This pathway amplifies inflammation, which can become damaging in septic shock. Reducing receptor engagement is intended to lower excessive inflammatory signaling.
Soluble TREM-1 is used as a marker of pathway activation. Selecting patients with higher biomarker values is a development strategy, not itself proof of treatment efficacy.
Sources: [1]
Approval and ASTONISH results
No FDA approval is described. Development has continued toward a possible biomarker-enriched Phase III program.
| ASTONISH Phase IIb analysis | Organ-failure result |
|---|---|
| Predefined high-biomarker group | Improvement was not statistically significant. |
| Overall population | Improvement was not statistically significant. |
| Higher biomarker cutoffs | A clinically relevant subgroup signal was reported, requiring confirmation. |
The company initially characterized the results positively, but the peer-reviewed report states that the primary endpoint was not achieved. The controlled evidence does not establish benefit; the subgroup should not be reported as a positive overall trial.
References and further reading
This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .
- 10.1016/S2213-2600(23)00158-3TREM-1 amplification and biomarker strategyCited in: TREM-1 amplification and biomarker strategy
Frequently Asked Questions About Nangibotide
Related Peptides
Continue exploring Nangibotide
Search all related references →Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.